Product Information
PREGABALIN ER 165 MG TABLET is a generic product labeled by Novadoz Pharmaceuticals LLC, priced at $1.8143 per EA under NDC 72205007830. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Apr 13, 2021. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the PREGABALIN market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
165 mg/1
Manufacturer
Novadoz Pharmaceuticals LLCNDC
72205007830
Classification
Generic
Dosage Form
TABLET, FILM COATED, EXTENDED RELEASE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
PREGABALINApproval Type
Generic (ANDA)
FDA Application
ANDA213226FDA Approved
4/13/2021
TE Code
AB
On Market Since
4/13/2021
Price Statistics
The NADAC for PREGABALIN ER 165 MG TABLET has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 45.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.8143 per EA |
|---|---|
| All-time high | $3.6487 (Jun 11, 2025) |
| All-time low | $1.7885 (Aug 21, 2024) |
| 52-week high | $2.5577 |
| 52-week low | $1.8143 |
| Median price | $2.3215 |
| Average price | $2.5294 |
| Largest weekly change | -30.2% (Aug 21, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the PREGABALIN market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Novadoz Pharmaceuticals LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
PREGABALIN market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of PREGABALIN ER 165 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for PREGABALIN ER 165 MG TABLET, manufactured by Novadoz Pharmaceuticals LLC, is $1.8143 per EA (NDC 72205007830), effective Sep 30, 2026.
How has the price of PREGABALIN ER 165 MG TABLET changed over time?
Over the history we have for it, the NADAC for PREGABALIN ER 165 MG TABLET has declined 45.4%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for PREGABALIN ER 165 MG TABLET?
Since Apr 17, 2024, the NADAC for PREGABALIN ER 165 MG TABLET has ranged from a low of $1.7885 (Aug 21, 2024) to a high of $3.6487 (Jun 11, 2025), with a median of $2.3215 per EA.
Are there cheaper alternatives to PREGABALIN ER 165 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of PREGABALIN ER 165 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures PREGABALIN ER 165 MG TABLET?
PREGABALIN ER 165 MG TABLET (NDC 72205007830) is labeled by Novadoz Pharmaceuticals LLC, and CMS classifies it as a generic product.